2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2664

Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2381

Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2577

Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2575

Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2271

Long-Term Efficacy and Safety of Adalimumab By Immunosuppressant Use in Patients with Non-Infectious Uveitis

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: L13

Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial

Late-Breaking Abstract Poster Session

9:00AM-11:00AM: Abstract Number: 2606

Long-Term Inhibition of Radiographic Progression with Originator Adalimumab in Patients with Moderate to Severe Psoriatic Arthritis with or without Radiographic Damage at Baseline

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2516

Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2779

Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2429

Long-Term Outcome of Children Born to Mothers with Chronic Arthritis and Exposed to TNF-Inhibitors during Pregnancy: A Case-Control Study

Reproductive Issues in Rheumatic Disorders Poster

9:00AM-11:00AM: Abstract Number: 2261

Long-Term Outcome of Pulmonary Sarcoidosis: A Population-Based Cohort Study from 1976-2013

Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease

9:00AM-11:00AM: Abstract Number: 2379

Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2527

Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2509

Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years’ Treatment

Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds

9:00AM-11:00AM: Abstract Number: 2629

Longitudinal Analysis of Persistent Positivity of Antiphospholipid Antibodies in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].